News After phase 3 hit, Spine seeks path forward for pain drug The first phase 3 readout with Spine BioPharma's drug candidate for chronic low back pain has proved disappointing.
R&D On genomics, NGS, and doing much more good than bad, with Ma... Markus Vossman, Germany general manager at Illumina, discusses innovative genomic applications and projects in the region.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
